Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10525 |
SCD1 inhibitor-4
|
Dehydrogenase; Stearoyl-CoA Desaturase (SCD) | Metabolism |
SCD1 inhibitor-4 是一种具有口服活性的 stearoylCoA desaturase-1 抑制剂,可用于研究糖尿病。 | |||
T38683 |
SCD1 inhibitor-3
SCD1-IN-3,SCD1 inhibitor-3,SCD1 inhibitor 17a |
Dehydrogenase | Metabolism |
SCD1 inhibitor-3 (ML-270) 是一种高效、口服的化合物,可以抑制SCD1,且安全性极高。 SCD1 inhibitor-3 显示出在代谢疾病(包括肥胖、二型糖尿病和血脂异常,以及痤疮和癌症等各种皮肤病)方面的巨大研究潜力。 | |||
T5427 |
GSK1940029
SCD inhibitor 1 |
Dehydrogenase; Stearoyl-CoA Desaturase (SCD) | Metabolism |
GSK1940029 (SCD inhibitor 1) 是酰基-辅酶A 去饱和酶 (SCD) 抑制剂。 | |||
T1869 |
PluriSIn 1
4-吡啶羧酸 2-苯基酰肼,NSC 14613,PluriSIn #1,PluriSln 1 |
Apoptosis; Dehydrogenase; Stearoyl-CoA Desaturase (SCD) | Apoptosis; Metabolism |
PluriSIn 1 (NSC 14613) 是一种酰基-辅酶 A 去饱和酶抑制剂,是一种多能细胞特异性的抑制剂。 | |||
T71175 |
SCD1 Inhibitor
|
||
SCD1 Inhibitor is a novel stearoyl-CoA desaturase1 (SCD1) inhibitor. | |||
T12863 |
SCD1 inhibitor-1
|
Others | Others |
SCD1 inhibitor-1 is a potent and liver-selective inhibitor of stearoyl-CoA desaturase-1 (SCD1). | |||
T2650 |
MK-8245
|
Dehydrogenase; Stearoyl-CoA Desaturase (SCD) | Metabolism |
MK8245 是肝靶向的硬脂酰 -CoA 去饱和酶(SCD)抑制剂,对人 SCD1 和鼠 SCD1 的IC50值分别为 1 nM 和 3 nM,具有抗糖尿病和抗血脂异常的作用。 | |||
T9003 |
CVT-11127
N-[2-[6-[[(3,4-二氯苯基)甲基]氨基]-2-(4-甲氧基苯基)-3-氧代-3,4-二氢吡啶并[2,3-B]吡嗪-4-基]乙基]乙酰胺 |
Dehydrogenase | Metabolism |
CVT-11127 是 SCD 抑制剂。它将细胞周期阻滞在 G1/S 期,诱导细胞凋亡。它可用于肺癌的研究。 | |||
T73188 |
RK-0133114
|
||
RK-0133114 是G9a 抑制剂,也是RK-701 的 R-对映体。RK-0133114 抑制 G9a 的IC50值为 3.7 μM。RK-0133114 可用于镰状细胞病 (SCD) 的研究。 | |||
T64171 | LXR antagonist 2 | ||
LXR antagonist 2 (compound 10rr) 是一种有效的 LXR (肝 X 受体) 反向激动剂,能够作用于 LXRβ (IC50: 0.36 μM) 和 LXRα (IC50: 2.25 μM)。 LXR antagonist 2 是一种脂肪生成抑制剂,能够下调 LXR 靶基因 SREBP-1c、ACC、FAS 和 SCD-1。LXR antagonist 2 对 Triton WR-1339 诱导的高脂血症小鼠表现出降脂活性。 | |||
T38844 |
MK-8245 Trifluoroacetate
|
||
MK-8245 trifluoroacetate is a liver-targeting inhibitor of stearoyl-CoA desaturase (SCD) with IC50 of 1 nM for human SCD1 and 3 nM for both rat SCD1 and mouse SCD1, with anti-diabetic and anti-dyslipidemic efficacy. IC50 value: 1 nM (hSCD1) Target: SCD1 in vitro: MK-8245, a phenoxy piperidine isoxazole derivative, has been identified as a potent and liver-specific SCD inhibitor. It contains a tetrazole acetic acid moiety, which is the key molecule for OATPs recognition and liver-targeting. MK... |